TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02908308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted temperature management to 33°C
Description: Rapid cooling to below 33°C, followed by temperature control at 33°C for up to 28h.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care with early treatment of fever
Description: Normothermia and standard care - use of a device for temperature control if temperature is greater than or equal to 37.8°C
Study: NCT05516225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBCLN-003
Description: Human Milk Oligosaccharide Concentrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBCLN-003
Description: Human Milk Oligosaccharide Concentrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBCLN-003
Description: Human Milk Oligosaccharide Concentrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBCLN-003
Description: Human Milk Oligosaccharide Concentrate
Study: NCT03716375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrapleural Medications
Description: urokinase
Study: NCT01597830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobility shoe
Description: flat, specialized shoe

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control shoe
Description: control shoe
Study: NCT02862379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based program
Description: The objective of the rehabilitation program is to reduce the risk of falls after management of the risk factors identified. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors
Study: NCT02857530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: without rhTPO
Study: NCT03610464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine Extended Release Suspension [Dyanavel]
Description: 1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis
Study: NCT00489710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talabostat mesylate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: enzyme inhibitor therapy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: non-specific immune-modulator therapy
Study: NCT06221423

Intervention type: DRUG
Intervention: Fruquintinib Combined With TAS-102
Description: Fruquintinib Combined With TAS-102
Study: NCT00153998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab and FOLFIRI
Description: Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab and FOLFOX
Description: Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)
Study: NCT03654781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple therapy
Description: triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple therapy
Description: triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: professional periodontal treatment
Description: periodontal treatment consisting of mechanical periodontal treatment (scaling and root planing) Oral hygiene insruction Periodontal treatment started concurrently with triple therapy
Study: NCT02526355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile based intervention
Description: Learning through Play Plus Intervention delivered through mobile phone
Study: NCT04242693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile goal-setting intervention
Description: This intervention applied two constructs from the goal setting theory-self-monitoring and goal setting. Briefly, all participants were asked to take photos of all their meals and upload them with descriptions to an online platform. The participants in the experimental group were taken through two additional processes that represented these two constructs. Self-monitoring was operationalized by asking those in the experimental group to count the number of times they ate red/orange vegetables using a counting checklist. Goal setting was operationalized as asking them to set a goal to eat red/orange vegetables one more time tomorrow.
Study: NCT02547870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV)
Description: Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV)
Description: Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)
Description: Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aged RPV-LA
Description: Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
Study: NCT02731625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kettlebell training
Description: Kettlebell training will be performed in 30 second work:rest intervals. Total training time will progress from 10 minutes at the beginning of the study to 20 minutes at the end.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Army Physical Readiness Training
Description: Army Physical Readiness Training per Army Field Manual 7-22

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Army Physical Readiness Training
Description: Army Physical Readiness Training per Army Field Manual 7-22
Study: NCT02799784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI
Description: ELLIPTA dry powder inhaler (DPI) will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5 mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIO/OLO
Description: TIO/OLO inhalation spray will be supplied as an inhalation spray delivered using a RESPIMAT inhaler. Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent to 2.5 mcg olodaterol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be supplied as an inhalation spray via metered dose inhaler and will be issued for reversibility testing at Visit 1. Albuterol/salbutamol will be permitted throughout the study for use as-needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be supplied as an inhalation spray via metered dose inhaler and will be issued for reversibility testing at Visit 1. Albuterol/salbutamol will be permitted throughout the study for use as-needed
Study: NCT01363336

Intervention type: DRUG
Intervention: Nifedipine (Adalat CR, BAYA1040)
Description: patients who are administrated with Adalat CR for hypertension
Study: NCT02024477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5 mg tablet once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily for 12 weeks
Study: NCT02245464

Intervention type: DRUG
Intervention: Telmisartan
Study: NCT04276636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caltrate Pill
Description: Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
Study: NCT01291914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX005
Description: Single Ascending Dose (SAD) Phase Cohorts: 1, 10 or 45 mg intra-articular injection; Proof of Concept Phase: Maximum, well-tolerated dose intra-articular injection (determined during SAD Phase)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1 (Carrier)
Description: Single intra-articular injection
Study: NCT00672672

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: autologous platelet gel
Description: Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous platelet gel
Description: Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
Study: NCT03722485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)
Description: Negative Pressure Therapy at -125mmHg for 3.5 hours followed by 10 minute dwell of saline solution for 6-9 days.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Ointment
Description: Collagenase ointment applied daily to the wound and covered with secondary dressing for 6-9 days.
Study: NCT03698305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5354
Description: Intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study: NCT03968744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Description: Safinamide taken per Os for 12 weeks
Study: NCT01341444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena Incision Management System
Description: It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care for Surgical Incisions
Description: Sterile 4X4 Non-Penetrable barrier
Study: NCT01316809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8055
Description: Patients will start at 120 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8055
Description: Patients will start at 120 mg once daily
Study: NCT01291914

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2 (Diluent)
Description: Single intra-articular injection
Study: NCT02157480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .
Description: outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2\* (DJO, Vista, CA, USA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week
Description: outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2\* (DJO, Vista, CA, USA)
Study: NCT03988634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: Sacubitril/valsartan (LCZ696) was available as 24/26 mg, 49/51 mg, and 97/103 mg in tablet form to be taken orally, twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Valsartan was available as 40 mg, 80 mg, and 160 mg in tablet form to be taken orally, twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sacubitril/valsartan matching placebo
Description: Sacubitril/valsartan (LCZ696) matching placebo was available as tablet form to be taken orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan matching placebo
Description: Valsartan matching placebo was available as tablet form to be taken orally, twice daily
Study: NCT00954954

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PS RP-MB (P.F.C Sigma Rotating Platform knee)
Description: Comparison of different types of knee prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flexion PS RP-MB (P.F.C Sigma Rotating Platform Flex)
Description: Comparison of different types of knee prosthesis
Study: NCT04177225

Intervention type: PROCEDURE
Intervention: Trans thoracic Ultrasound Examination
Description: Ultrasound examination of cardiac function before and after induction of general anesthesia.

Intervention type: PROCEDURE
Intervention: Trans thoracic Ultrasound Examination
Description: Ultrasound examination of cardiac function before and after induction of general anesthesia.

Intervention type: OTHER
Intervention: Intravenous fluid administration
Description: Intravenous fluids will be administered as a bolus in response to standard clinical indications

Intervention type: OTHER
Intervention: Intravenous fluid administration
Description: Intravenous fluids will be administered as a bolus in response to standard clinical indications
Study: NCT04049747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]
Description: Radical therapy (radiotherapy or prostatectomy \[radiotherapy can be external beam or brachytherapy\]

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]
Description: Radical therapy (radiotherapy or prostatectomy \[radiotherapy can be external beam or brachytherapy\]

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal therapy
Description: Focal therapy (high intensity focused ultrasound or cryotherapy)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal therapy after Finasteride 5Mg tablets for 12 weeks
Description: finasteride 5mg tablets 12 weeks prior to focal therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal therapy after Bicalutamide 50Mg tablets for 12 weeks
Description: Bicalutamide 50mg per day - 12 weeks prior to focal therapy
Study: NCT02496338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program about menopausal health isues
Description: A three sessions raining program about health issues during menopause for spouses of 45-60 years old
Study: NCT00082732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic dietary intervention
Study: NCT02897479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Enrolled patients will be treated with Savolitinib 600mg or 400mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
Study: NCT03375476

Intervention type: DIAGNOSTIC_TEST
Intervention: collection of cardiovascular risk scores and intraoperative cardiovascular parameters
Description: collection of preoperative cardiovascular risk scores and intraoperative cardiovascular parameters

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac troponin assay
Description: plasmatic concentration of high sensitive cardiac troponin will be measured at baseline and on postoperative day 1, 2 and 3

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: 12 derivations ECG will be made at baseline and on postoperative day 1, 2, and 3
Study: NCT01287611

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Purse string closure technique
Description: Uterine Kerr incision will be closed with purse string suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuously locked closure technique
Description: Uterine Kerr incision will be closed with continuously locked suturing
Study: NCT01572389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Outcomes through Patient Empowerment (HOPE)
Description: HOPE participants will receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period followed by usual primary care during the subsequent 6 months maintenance period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: All participants receive usual VA primary care plus a dedicated screening for diabetes control and clinically significant depressive symptoms. Patients and primary care providers are notified of these results and given recommendations for usual care.
Study: NCT03532308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermented Soy
Description: Two 12.5g packets/day) (\~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Time can be between 4 and 10 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo compliment to the active intervention with identical packaging and labeling will be used.
Study: NCT01645748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is an oral fluoropyrimidine derivative, based on the concept of biochemical modulation. It consists in a molar ratio of 1:0.4:1: tegafur, a prodrug that is slowly metabolized to 5-fluorouracil; gimeracil, which reversibly inhibits dihydropyrimidine dehydrogenase. In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively. Another phase II study of TPS as induction chemotherapy for locally advanced HNSCC was determined to be 70/70/60 mg∙m2/d every 3 weeks. However, the rate of grade 3-4 neutropenia was 75% at this recommended dose. To reduce the hematologic toxicities, we used the docetaxel weekly. Therefore following regimen was evaluated in this study; docetaxel 30 mg/m2 (D1, D8), cisplatin 60mg/m2 (D1), S-1 70mg/m2 (D1-D14) every 3 weeks.
Study: NCT02768662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104
Description: Single intratympanic injection of 12 mg OTO-104
Study: NCT04193501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Description: Melatonin dose: 3mg/OD Melatonin is a hormone made by the pineal gland; its biosynthesis is initiated by the uptake of the essential amino acid tryptophan and is an important inducer of sleep. Abnormality in melatonin has been shown in several studies on patients of IBS and functional constipation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar looking placebo
Study: NCT01969019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone, prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone, prednisone
Study: NCT00906048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin (HR355) and Rifampicin Therapy
Description: Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day~Weight \< 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight \> 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin
Study: NCT02277990

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TYRX™ Absorbable Antibacterial Envelope
Study: NCT04665011

Intervention type: DEVICE
Intervention: Indicor
Description: A simple, non-invasive tool to report pulse response to a Valsalva maneuver

Intervention type: DEVICE
Intervention: Caretaker
Description: non-invasive blood pressure monitor
Study: NCT02019628

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice Bran Arabinoxylan Compound (RBAC)
Description: Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice Bran Arabinoxylan Compound (RBAC)
Description: Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.